Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
US-12173314-B2 · Dec 24, 2024 · US
Light-activated cation channel and uses thereof
US9101690B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101690-B2 |
| Application number | US-201213555981-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 23, 2012 |
| Priority date | Jul 22, 2005 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.
First claim
Opening claim text (preview).
What is claimed is: 1. An implantable prosthetic device comprising a cell expressing a channelrhodopsin, wherein the channelrhodopsin comprises an amino acid sequence having at least about 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1, and wherein the cell is a retinal cell, a spiral ganglion cell, or a neuron. 2. The implantable device of claim 1 , wherein the channelrhodopsin comprises an amino acid sequence having at le…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101690B2 cover?
- The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisec…
- Who is the assignee on this patent?
- Deisseroth Karl, Boyden Edward S, Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification A61L27/3604. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).